NEW YORK--(BUSINESS WIRE)--Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, announced today that it has restructured its license agreement with Genzyme Corporation (Nasdaq: GENZ) for Atiprimod, Callisto’s lead drug in the clinic to treat advanced carcinoid cancer.
